Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynamis Therapeutics has discovered a new class of compounds that inhibit the production of Rage, the receptor for advanced glycation end products.
Subscribe to our email newsletter
A team of scientists at Dynamis significantly decreased kidney and retina Rage in aged rats that were orally dosed with company’s Rage inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited Rage in a variety of cells grown in culture.
Scientists believe that a Rage inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer’s, inflammatory diseases, some cancers, and aging. A patent has been filed on the discovery.
Annette Tobia, president and founder of Dynamis, said: “We are very excited about these results, since discovering Rage inhibitors enables company to develop a treatment for diabetic kidney disease and blindness.”